Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Declines By 78.9%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totaling 6,640 shares, a decrease of 78.9% from the August 15th total of 31,402 shares. Based on an average daily volume of 300,155 shares, the days-to-cover ratio is presently 0.0 days.

SAB Biotherapeutics Stock Performance

NASDAQ SABSW traded up $0.01 during trading on Friday, hitting $0.03. The company’s stock had a trading volume of 47,595 shares, compared to its average volume of 77,775. SAB Biotherapeutics has a 52 week low of $0.00 and a 52 week high of $0.20. The firm has a 50 day moving average price of $0.02 and a 200 day moving average price of $0.02.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.

The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.